Hennion & Walsh Asset Management Inc. Has $4.42 Million Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Hennion & Walsh Asset Management Inc. raised its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 13.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 35,894 shares of the specialty pharmaceutical company's stock after acquiring an additional 4,332 shares during the period. Hennion & Walsh Asset Management Inc. owned approximately 0.06% of Jazz Pharmaceuticals worth $4,420,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC lifted its holdings in shares of Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock valued at $30,000 after acquiring an additional 97 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Jazz Pharmaceuticals by 41.3% during the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company's stock worth $46,000 after purchasing an additional 121 shares in the last quarter. Cooper Financial Group boosted its position in shares of Jazz Pharmaceuticals by 3.7% in the fourth quarter. Cooper Financial Group now owns 4,334 shares of the specialty pharmaceutical company's stock worth $534,000 after buying an additional 156 shares during the period. Coldstream Capital Management Inc. grew its stake in shares of Jazz Pharmaceuticals by 7.7% in the third quarter. Coldstream Capital Management Inc. now owns 2,300 shares of the specialty pharmaceutical company's stock valued at $259,000 after buying an additional 165 shares in the last quarter. Finally, Itau Unibanco Holding S.A. grew its stake in shares of Jazz Pharmaceuticals by 63.2% in the third quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company's stock valued at $49,000 after buying an additional 172 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock traded down $0.62 on Thursday, hitting $122.62. 357,287 shares of the stock traded hands, compared to its average volume of 490,529. The company has a market capitalization of $7.41 billion, a PE ratio of 17.27, a PEG ratio of 0.88 and a beta of 0.56. The company's fifty day moving average is $122.76 and its 200 day moving average is $114.44. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $134.17.

Analyst Upgrades and Downgrades

JAZZ has been the subject of a number of analyst reports. TD Cowen decreased their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating for the company in a report on Thursday, November 7th. Morgan Stanley upgraded shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and upped their target price for the company from $140.00 to $175.00 in a research note on Thursday, December 12th. HC Wainwright reaffirmed a "buy" rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Needham & Company LLC restated a "buy" rating and set a $207.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Finally, Robert W. Baird boosted their price target on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an "outperform" rating in a research note on Monday, November 18th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $177.00.

Insider Transactions at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 3,700 shares of the business's stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the sale, the executive vice president now owns 33,048 shares of the company's stock, valued at $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total value of $185,145.00. Following the transaction, the chief executive officer now directly owns 425,525 shares of the company's stock, valued at approximately $52,522,550.75. The trade was a 0.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 8,253 shares of company stock worth $1,001,434. 4.20% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.